Sequential imaging of genetically marked effector cells after adoptive transfer in vivo has greatly enhanced analyses of their biodistribution, growth, and activity both in animal models and in clinical trials of cellular immunotherapy. However, the immunogenicity of cells expressing xenogeneic reporter constructs limits their survival and clinical utility. To address this limitation, we have evaluated a human norepinephrine transporter (hNET) permitting imaging of transduced cells in vivo with a previously approved clinical grade radiolabeled probe, metaiodobenzylguanidine (MIBG). The hNET gene cDNA was cloned from the SK-N-SH cell line and inserted into a bicistronic retroviral vector also encoding green fluorescent protein. Following transfection, human EBVspecific T lymphocytes were fully functional in vitro and also selectively accumulated [ 123
Introduction
Evaluations of biological therapies targeting human malignancies increasingly depend on thorough monitoring of the biodistribution and ultimate disposition of the therapeutic agents following their introduction into the organism and throughout the course of their treatment effects. Molecular gene imaging offers a convenient tool for noninvasive observation of the biological processes in live subjects and also in real time (1) . However, effective clinical translation has been subject to several limitations (2) , particularly the immunogenicity of the reporter gene product. Use of a protein of human origin as the reporter may circumvent this problem. Several human reporter genes have been developed, including human dopamine D2 receptor (hDDR2), human sodium iodine symporter (hNIS), and human somatostatin receptor subtype 2 (hSSTR2; refs. [3] [4] [5] [6] [7] . Another is the human norepinephrine transporter (hNET; ref. 8 ), a protein involved in the transport of norepinephrine analogues into cells. Its properties have been used for heart imaging and for detection of malignancies of neural crest origin (e.g., neuroblastoma and pheochromocytoma; refs. 9, 10). is a standard, clinically approved radiolabeled probe for imaging tissues expressing high levels of hNET (11, 12) . Thus, hNET has several potential advantages as a reporter: (a) it is a human protein that should minimize its immunogenicity; (b) a radiolabeled probe for imaging hNET expression is currently used in the clinic; (c) this probe, MIBG, can be radiolabeled with 123 I or 131 I for single-photon emission computed tomography (SPECT) and g-camera imaging and with 124 I for positron emission tomography (PET) imaging. In this study, we have examined the feasibility of using the hNETbased reporter system for noninvasive in vivo imaging of human antigen-specific CTLs in a murine model of adoptive immune cell therapy of human EBV-associated lymphoma with [
123 I]MIBG and SPECT or [
124 I]MIBG and PET. We also evaluated the potential of hNET, when used in combination with a second clinically applicable reporter, for dual-modality imaging to monitor two separate lymphocyte subpopulations in vivo.
Materials and Methods
Cloning cDNA for hNET and construction of retroviral vectors for directing constitutive expression of hNET. The hNET gene was cloned as described previously (8) . Specific primers (GeneLink) were designed for the 3 ¶ and 5 ¶ ends of the cDNA sequences of hNET, described in the sequence database (NM_001043, M65105). hNET cDNAs were amplified by reverse transcription-PCR from the neuroblastoma cell line SK-N-SH (American Type Culture Collection; ref. 8) . After separation in agarose gel, a band corresponding to the molecular weight of hNET was extracted, purified, and used for vector production according to techniques described previously (8) . Briefly, cDNA fragments were cloned into the pGEM-TEasy vector (Promega) and checked using standard T7 and SP6 primers. The product was ligated with pQCXIX (Clontech). An hNET-IRES fragment was obtained from the resulting pQChNETIX plasmid using BamHI and XhoI endonucleases (New England Biolabs) and cloned into pLEGFP-N1 backbone using the BglII and XhoI insertion sites. The precise vector used for transduction, which is pLhNETiGFP, is produced by insertion of hNET-IRES fragment into pLEGFP-Nq plasmid (Clontech). The DNA obtained was used to transfect a packaging cell line, H29, for subsequent transduction of the retroviral producer cell line, PG-13 (Clontech).
Cell line transduction, selection, and testing. The technique used for transduction of the T cells is based on that described by Pollok et al. (13) as modified for transduction of T cells specifically sensitized with autologous EBV-transformed B cells (EBV-BLCL; refs. 14, 15). Briefly, aliquots of 2 mL/well of isolated T cells prestimulated with autologous irradiated EBV-BLCL for 8 days were cultured for 8 h at a concentration of 1 Â 10 6 /mL in nontissue culture six-well plates (Costar) coated with 15 Ag/cm 2 retronectin (recombinant human fibronectin fragment CH-296, Takara Bio, Inc.) together with a 35-fold concentrate of cell-free retroviral vector-containing supernatant from the PG-13 cells at a final concentration of 10 7 infectious viral particles/mL (multiplicity of infection = 10; as determined by terminal dilution transfection of Jurkat cells) and 8 Ag/mL polybrene (American Bioanalytical). After washing and culturing for 12 h, the transduction was repeated. Thereafter, the washed cells were incubated for 3 days in Yssel's medium supplemented with 5% heat-inactivated human serum and 10 units/mL of recombinant human interleukin-2 (IL-2; Chiron, Inc.) at a concentration of 0.6 Â 10 6 T cells/mL. The transduced T cells were then analyzed and sorted in a FACSCalibur sterile sorter (Becton Dickinson).
Separate aliquots of T cells from the same CTL line were simultaneously transduced with a previously described TK-eGFP vector following the same protocol for transduction and sorted by expression of green fluorescent protein (GFP). In separate experiments, subsets of CD4 + and CD8 + EBV-specific T lymphocytes were fractionated from the parental line by fluorescence-activated cell sorting (FACS) of cells stained with fluorescent anti-CD4 or anti-CD8 antibodies (Becton Dickinson), separately transduced with hNETiGFP and TK-eGFP vectors, respectively, and selected by FACS based on GFP expression. Expression of hNET was assessed by FACS staining with mouse antihuman NET antibodies (Mab Technologies, Inc.) and secondary goat antimouse phycoerythrin (PE)-conjugated antibodies (Becton Dickinson). The level and the rate of transporter activity were evaluated using a standard in vitro uptake assay (2, 14) by measuring the accumulation of specific ([ To assess the influence of the new reporter gene on transduced T cells, the proliferation and functional activity of CTL-hNETiGFP were compared with those of unmodified CTL or CTL-TKGFP of the same origin. Proliferation was assessed by monitoring the total number of viable cells in the CTL cultures at specified intervals. To assess the influence of specific radiolabels on the EBV-specific cytotoxicity of CTL-hNETiGFP, CTL-TG, and unmodified CTL, each cell type was preincubated for 3 h with 0. HLA alleles with the T-cell donor as described previously (14) and compared with the responses of the same T cells incubated with medium alone.
Human EBV lymphoma xenograft model. For the in vivo imaging studies, we used a model of adoptive cell therapy previously developed in our laboratory (14, 16) . Briefly, as required for specific experiments, groups of at least three and up to five nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice received one or four anatomically separated s.c. inoculations of different human EBV-BLCL (BLCL) or human leukemic cells, varying in expression of EBV and/or HLA alleles (3 Â 10 6 to 5 Â 10 6 cells per injection). Sorted populations of CTL-hNETiGFP or CTL-TKGFP were given either intratumorally or i.v. when measurable tumors were detected at all sites. At specified times thereafter, the animals received i.v. infusions of the specific radiolabeled probes and were subsequently imaged by PET or SPECT.
PET imaging was performed on a MicroPET-IIR (Concorde) scanner using 15-min list-mode acquisition of a single static frame (energy range, 420-580 keV). Images were obtained weekly 4 or 24 h after administration of I-labeled MIBG or FIAU. A structural image of the animal using CT scan was obtained with 128 frames immediately following the SPECT acquisition. Image reconstruction was performed using filtered back projections applying a Butterworth 50 filter 0.4. CT scans were reconstructed using Cobra software. Coregistration of CT and SPECT images was performed on X-SPECT with the vendor's software.
Statistical analysis. The coefficient of determination (R-squared) was used to assess the fit of the regression line to the data points. The R-squared statistic ranges between zero and one, where a value of one indicates a perfect fit of the regression line to the data and a value of zero represents that a linear relationship does not exist between the two variables under study. A P value was generated to provide a level of evidence that a linear relationship exists between each pair of variables. For paired comparisons of samples, the m 2 and Fisher's exact tests were applied.
Results
Characterization of EBV-CTL transduced to express hNET reporter gene system. Sequencing analysis showed identity of 5 ¶ and 3 ¶ ends of cloned hNET with the published National Center for Biotechnology Information sequence (M65105). Following pLhNET-iGFP retroviral vector transfection, >25% of primary EBV-CTL expressed hNET and GFP, which were then selected by GFP expression to 98% purity (Fig. 1A) .
[ 123 I]MIBG accumulation in hNET-transduced primary human antigen-specific T lymphocytes in vitro. The influx constant K1 was 1.8 F 0.5 mL/min/g and the steady-state accumulation level, K1/K2, was 58.6 F 6.8 mL/g. The mean value for the accumulation observed at 60 min in three repeated tests was 58.5 F 3.0 mL/g. This level of in vitro activity of the hNET reporter was slightly higher than that of HSV-TK, as measured by accumulation of [ 124 I]FIAU detected in CTL-TKGFP. We therefore hypothesized that in vivo MIBG uptake of CTL-hNETiGFP would be sufficient to yield images at least comparable with those achievable using [
124 I]FIAU to image HSV-TK-transduced cells ( Fig. 1B; ref. 14) .
CTL-hNETiGFP proliferated in response to antigen-specific stimulation (Fig. 1D) at levels similar to those detected in unmodified CTL or CTL-TKGFP from the same EBV-specific T-cell line. They also exhibited comparable HLA-restricted EBV-specific cytotoxicity (data not shown). The level of EBV-specific cytotoxicity of CTL-hNETiGFP was not affected by preincubation of the T cells with unlabeled MIBG or MIBG labeled with either 123 I or 124 I when compared with CTL-TKGFP or nontransduced EBV-specific T cells from the same line (Fig. 1C) .
Sensitivity of PET and SPECT for imaging hNET + T cells in vivo. We initially wished to determine the number of CTLhNETiGFP detectable in a targeted tumor in vivo. In these experiments, we also wished to gain an initial assessment of the capacity of PET to image EBV-specific CTLhNETiGFP accumulating [
124 I]MIBG when compared with EBVspecific CTL-TKGFP, which, as we previously reported (14) (Fig. 2D) . However, the steeper slope of the plot in Fig. 2D suggests that PET imaging of Figure 1 . A, FACS analysis of iGFP (left column ) and hNET (right column) expression in EBV-specific CTLs transduced with hNET-GFP vector. Unsorted population (top row ) of the EBV-specific T cells was analyzed for the expression of GFP (FITC channel) and hNET (PE channel) after transduction with the retroviral vector encoding these proteins and showed equal proportions of GFP-and hNET-expressing cells. Top, human CTLs (25.8%) transduced with the pLhNET-iGFP retroviral vector (CTL-hNETiGFP) were positive for GFP and 26.8% for hNET by FACS. After cell sorting, >93% of the T cells were GFP positive (A, middle ), of which 98% stained with anti-hNET antibodies (B, middle ). Bottom, the negative population of T cells depleted by FACS sorting of GFP + cells contained <1% of GFP + population and <3% of those cells stained with the anti-hNET antibodies. Characterization of the hNETiGFP-transduced EBV-specific T lymphocytes. B, in vitro accumulation of Quantitative Imaging of hNET-Transduced CTL www.aacrjournals.org CTL-TKGFP may be more sensitive for quantitations of T cells accumulated.
Of note, the whole-body PET images obtained within 4 h after i.v. infusion of each radiotracer also showed high level of radioactivity in the gut and urinary tract caused by excretion of the 124 I metabolites ( Fig. 2A and C) . These nonspecific accumulations were detected both in the animals that had received intratumoral injections of T cells and in control animals that had not received injections of T cells. Although these nonspecific accumulations can be avoided by obtaining PET images 24 h after infusion of the radiotracer (additional images not shown; ref. 4 hNETiGFP + T cells could also be imaged by this modality (Fig. 3A) . Application of dual-modality imaging with CT overlapping the SPECT image permitted exact localization of the increased radiotracer accumulation area to the tumor. Again, measurements of signal intensity showed a direct correlation between signal intensity and dose of T cells injected in each tumor (P < 0.001; Fig. 3B ). As expected, and consistent with our prior studies (14) , there was also a close correlation between the amount of radiotracer detected by the g-spectrometer well counter in the tumors and the dose of hNET + T cells previously injected into the tumor. Measurements of accumulation of EBV-specific CTL-hNETiGFP in a target tumor over extended time intervals. In our prior studies, we had shown that accumulations of EBV-specific T cells transduced to express HSV-TK in targeted xenografts could be imaged in vivo over a 2-week period by sequential infusions of [ 124 I]FIAU followed by PET. To assess the utility of hNET as a reporter for long-term monitoring of EBV-specific T cells, EBVspecific CTL-hNETiGFP at doses of 12 Â 10 6 CTL-hNETiGFP per mouse was infused i.v. into five mice bearing a single s.c. tumor xenograft of autologous EBV-BLCL. At 1, 8, and 28 days after T-cell infusion, the animals were injected with 200 ACi/mouse [ 124 I]MIBG. Four hours thereafter, they were imaged by PET.
As shown in Fig. 4A , a progressive increase in the PET signal was detected in the tumors over 28 days. The number of T cells (Fig. 4B) . The initial accumulation of T cells in the tumors, calculated from the PET signal intensity of [ 124 I]MIBG activity as described earlier ( Fig. 2A) , was f0.5 Â 10 6 T cells and increased to f6 Â 10 6 T cells by day 28. As shown in Fig. 4B , there was a direct and significant correlation between cell numbers in each tumor calculated based on well count activity of [
124 I]MIBG in the targeted tumor and the signal accumulation recorded for each tumor by PET imaging (P < 0.001). The number of cells in the tumors calculated based on radioisotope accumulation was also significantly correlated with the number of GFP + T cells detected in the tumor (R 2 = 0.73; P = 0.043). PET and SPECT imaging of targeted accumulations of virusspecific CTL-hNETiGFP in EBV + tumors over time. Fig. 2 were also imaged by SPECT/CT 4.5 h after radiotracer administration. A, two sets of mice imaged by SPECT/CT with hNET standards. In the two sets, the juxtapositioning of mice injected with different T-cell doses was altered so as to permit image intensity comparisons within the maximal CT reconstruction diameter. Image coregistration was performed using X-SPECT software, combining two sets of axial reconstruction data. To eliminate the signal originating from the downscatter of [ Fig. 2 ; bottom, correlation between the number of CTL-hNETiGFP registered in the autologous EBV-BLCL tumor quantitated by accumulation of radiosignal in ROI on PET images and total well count activity. The numbers of T cells accumulated in tumors at days 1, 8, and 28 were calculated based on the standard image intensity to T-cell dose correlation and tumor accumulations of label to injected T-cell dose presented in Fig. 2 . There is a close correlation between the T-cell numbers calculated from direct measurement of radioactivity in the tissues and those calculated from quantitations of PET signal intensities in the ROI of the tumor.
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Cancer Res 2007; 67: (24 + EBV À tumor (T3). As expected, uptake of MIBG was increased in the heart and adrenal glands relative to normal tissues. Indeed, the accumulation of labeled MIBG in the T4 tumor detected at day 28 was only moderately greater than that detected in the heart and adrenal glands. Taken together, these studies of EBV-specific CTL-hNETiGFP confirm and extend our prior studies showing selective accumulation of EBV-specific, HLA class I-restricted CD8 + T cells in tumors expressing EBV and the restricting HLA allele (14) . Sequential imagings showed the ability of HLA class II-restricted CD4 + T cells to accumulate in tumors expressing EBV and their restricting allele (i.e., DRB 1 0402) but also showed that limited populations of antigen-specific T cells may not be imaged in targeted tissues until they have expanded to sufficient numbers to permit their detection.
Dual-modality imaging. Based on the comparable imaging of CTL-hNETiGFP and CTL-TKGFP, we explored whether these two reporters could be simultaneously used to evaluate the migration of two separate T-cell populations in the same animal.
As shown in Fig. 6A, after (T1) that is targeted by the HLA-A0201-restricted CD8 + EBVspecific T cells (Fig. 6B) . Selective accumulation of CD8 + or CD4 + T cells in T1 and T2 tumors, respectively, was confirmed by FACS analysis of T cells isolated from each tumor (Fig. 6C) . Thus, this sequential imaging approach permitted clear differentiation of the selective accumulations of two separate T-cell populations transduced to express distinguishable reporter proteins in the same mouse within 6 h on the same day.
Discussion
Currently, several reporter gene systems are being used in preclinical models to transduce normal or malignant cells so as to be able to image their migration, growth, and function in vivo (14, 17, 18) . However, the clinical applicability of many of these reporters is limited because the proteins they encode are immunogenic in man. Indeed, immune responses to certain reporter gene products have developed early after adoptive transfer of transduced cells and compromised evaluations of their tissue distribution and function (19, 20) . To address this limitation, attention has been focused on identification of human reporter genes encoding enzymes, receptors, or transport proteins with restricted expression in normal tissues, which can mediate differential uptake of radiolabeled drugs or biologicals. Three such genes have been reported previously: (a) hDDR2, by which cells differentially accumulate 3-(2 ¶-[
18 F]fluoroethyl)-spiperone (3, 6); (b) hSSTR2, expressed by carcinoid tumors, which differentially binds the somatostatin analogue [
111 In]diethylenetriaminepentaacetic acid-octreotide (4); and (c) hNIS, which mediates differential cellular uptake of either radiolabeled iodide or pertechnetate (2, 5) .
In this report, we evaluated the in vivo imaging of adoptively transferred lymphocytes transduced to express hNET, a human protein also unlikely to be immunogenic in man. The hNET protein is normally expressed on the plasma membrane of noradrenergic neurons at their synapses and acts to transport norepinephrine by endocytosis from the synaptic cleft back into the neuron. Although these transporters are normally expressed throughout the sympathetic system, cells expressing hNET are particularly concentrated in the adrenal glands and the heart (12).
In 1967, Morales et al. (21) first showed that [ 14 C]norepinephrine, infused into dogs, selectively accumulated in the adrenal medulla. Subsequently, radiolabeled MIBG, a structural analogue of norepinephrine that can block its neurotransmitter activity, was also shown to accumulate in the adrenal gland and could be used to image this organ (11) . In initial clinical trials, it was shown that [ 131 I]MIBG could be used to detect pheochromocytomas (9, 10) . It is now also extensively used for imaging and treatment of neuroblastoma (22) . In these tumors, uptake of [ 131 I]MIBG is based on their high level of expression of functional norepinephrine transporters.
For our study, we constructed a bicistronic retroviral vector directing the constitutive expression of hNET and GFP and transduced it into EBV-specific T cells of defined antigen specificity and HLA restriction. Following transduction, T cells expressing the vector-encoded GFP could be isolated in high purity by FACS. In vitro studies showed highly reproducible kinetics of radiotracer uptake in transduced T cells. Exposure of hNET-transduced EBVspecific T cells to MIBG or to MIBG labeled with either 124 I or 123 I did not alter their cytotoxic activity, confirming our previously published data that showed that the exposure of HSV-TKtransduced EBV-specific T cells to 124 I-or 131 I-labeled FIAU did not alter their EBV-specific HLA-restricted cytotoxicity in vitro or tumoricidal effect in vivo (14) .
In prior studies using this model, we were able to image EBVspecific HSV-TK/GFP-transduced T cells accumulating in targeted tumors by i.v. infusions of [ 124 I]FIAU followed by PET (14) . To gain initial estimation of the relative capacity of PET to detect transduced T cells, defined doses of EBV-specific CTL-hNETiGFP and CTL-TKGFP were directly injected into EBV-BLCL tumor xenografts and then imaged after i. (Fig. 2) . Furthermore, doses of as few as 10 4 CTLhNETiGFP or CTL-TKGFP could be clearly imaged. When mice were given [ 123 I]MIBG i.v. and imaged by X-SPECT, signal intensity in the tumors was also closely correlated with dose of T cells down to the lowest dose tested, 10 4 T cells per tumor (Fig. 3) . Fusion of CT and SPECT images permitted improved precision in the localization of the radiotracer accumulation sites.
Our group first showed the potential of PET imaging for longterm monitoring of antigen-specific T cells in vivo in studies of the migration of human EBV-specific T cells transduced to express an HSV-TK/GFP reporter gene (14) . Recently, other studies in murine tumor models have evaluated the short-term migratory patterns of unsensitized and antigenspecific T cells in vivo using PET to image T cells transduced to express HSV-TK (17, 24) or bioluminescence to track T cells transduced to express luciferase (25, 26) . In these studies, T-cell accumulations in targeted tumors have initially been evaluated and detected 3 to 4 days after adoptive transfer into the tumor-bearing mice and have increased over a subsequent 1 to 2 weeks of observation (24) . In studies using PET, quantitation of signal intensity emanating from the targeted tumors and other organs has been closely correlated with levels of radiolabel detected in each tissue. However, only one other study has directly correlated signal intensities over time with quantitation of transduced T cells detected in the tissue (24) . In that study, Su et al. used sequential PET imaging over 15 days to follow naive and memory-type ovalbumin-specific CD8 + T cells derived from OT-1 mice and expressing a mutant sr39-HSV-TK and GFP, after adoptive transfer into mice bearing transgenic tumors expressing ovalbumin. In that study, memory T cells rapidly accumulated in and eradicated Because interactions between different types of lymphocytes contribute to the kinetics, intensity, antitumor activity, and persistence of adoptive immune responses, a priority for our studies has been the development of technology permitting contemporaneous imaging of such interactions in vivo. In prior studies, Beilhack et al. (28) used bioluminescence imaging to examine the distribution and proliferation of splenic T cells expressing an in vivo luciferase transgene following transplantation into lethally irradiated H-2 disparate allogeneic hosts. During the course of graft-versus-host disease (GVHD), targeted tissues identified by their accumulations of luciferase + T cells were evaluated by immunohistochemistry for their content of different CD4 + and CD8 + T cells to distinguish the potential of alloresponsive naive and memory T cells to induce GVHD in vivo. However, this single reporter system did not permit continuous monitoring of each T-cell compartment in vivo. Alternative approaches using vectors encoding different bioluminescent reporters [e.g., firefly, Renilla reniformins, and click beetle luciferases (25) ], distinguishable by the substrates used and/or by the spectra of light emitted, have been used to contemporaneously monitor more than one transduced cell population in vitro and have been proposed for contemporaneous imaging of two to three cell populations in vivo. Development of such approaches is highly desirable because imaging by bioluminescence can be performed repeatedly at low cost and the background in tissues not containing cells expressing luciferase reporters is extremely low. However, to date, no studies have been reported in which different bioluminescent reporters have been used to successfully discriminate distinct cell populations in vivo. Furthermore, because the transmission of different light spectra through tissues differs, the accuracy of estimates of cell populations expressing certain luciferases when they accumulate in sites distant from the body surface may be limited.
In this report, we show that two T-cell populations bearing hNET and HSV-TK reporter genes can be contemporaneously imaged in vivo over extended intervals using SPECT + and HSV-TK-transduced CD8 + T cells, respectively. Although the possibility of such dual imaging has been raised by several groups interested in in vivo imaging techniques (29, 30) , this report is, to our knowledge, the first to show its feasibility. Furthermore, because our studies also indicate that the numbers of cells detectable by PET and SPECT are comparable, this approach may be of particular value for accurately measuring the accumulations of two different effector cell populations within a living subject. Both reporter systems used could also be applied clinically. However, additional preclinical trials beyond the scope of the current experiments as well as clinical trials will be required to ascertain the relative merits of each reporter and imaging modality for sequential long-term assessments of adoptively transferred cells in immunocompetent or immunoablated subjects.
Recent reports of leukemias developing in transduced cells in children with X-linked SCID late after treatment with autologous hematopoietic progenitor cells transduced with a retroviral vector encoding a normal IL-2 receptor (g-chain) have raised concerns about the tumorigenic potential of cells transduced with such vectors (31, 32) . Although long-term analyses of retrovirally transduced T cells following adoptive transfer into human patients and mice have thus far not detected either a dominance of integration sites or malignant transformation of transduced cells (33) (34) (35) , such concerns may limit broad use of such methods for imaging T cells until further and more extended safety data are accrued. Alternatively, other viral vectors or more efficient nonviral strategies, which may reduce or minimize risk of transformation, may be used to introduce reporter genes into these cells (36, 37) .
In conclusion, our studies indicate that the hNET vector described induces a level of expression of the hNET that permits effective imaging, with either [
123 I]MIBG and SPECT or [ 124 I]MIBG and PET of as few as 10 4 T cells accumulated in a 1 cm 3 tumor nodule. In these studies, the sensitivity of detection was comparable with that achieved by in vivo imaging of T cells transduced to express HSV-TK with PET after i.v. infusion of [ 124 I]FIAU. We also show the feasibility of contemporaneously imaging the in vivo biodistribution and targeted accumulation of two effector cell populations in the same animal by separately transducing each effector population to express a distinct reporter protein mediating the uptake of a radiolabeled tracer differentially imaged by SPECT and PET. Lastly, the close correlation observed between quantitation of signal intensity by PET and SPECT and the numbers of T cells directly injected into tumors or detected in targeted tumors after accumulation over time indicates the potential of such imaging strategies for quantitatively estimating the effector cell populations required for effective adoptive immunotherapy.
